IRTC:NSD-iRhythm Technologies Inc. (USD)

EQUITY | Medical Devices | NASDAQ Global Market

Last Closing

USD 137.7

Change

0.00 (0.00)%

Market Cap

USD 0.62B

Volume

0.49M

Analyst Target

USD 222.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-10 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

+0.38 (+0.45%)

USD 33.20B
PODD Insulet Corporation

+6.00 (+1.93%)

USD 21.86B
MASI Masimo Corporation

+6.99 (+4.46%)

USD 8.49B
BRKR Bruker Corporation

+2.74 (+7.30%)

USD 5.69B
PRCT Procept Biorobotics Corp

+1.32 (+2.48%)

USD 2.85B
TMDX TransMedics Group Inc

+7.23 (+6.48%)

USD 2.73B
LIVN LivaNova PLC

+1.17 (+2.66%)

USD 2.40B
SSII SS Innovations International I..

+0.06 (+0.59%)

USD 2.20B
NVCR Novocure Ltd

+1.19 (+6.85%)

USD 1.94B
QDEL Quidel Corporation

+1.08 (+2.97%)

USD 1.89B

ETFs Containing IRTC

EDOC:LSE Global X Telemedicine & D.. 4.53 % 0.00 %

+0.22 (+0%)

USD 4.27M
EDOG:LSE Global X Telemedicine & D.. 4.53 % 0.00 %

+0.20 (+0%)

USD 0.30M
FDHT:XETRA 2.58 % 0.00 %

N/A

N/A
KOMP SPDR Kensho New Economies.. 0.00 % 0.00 %

+1.59 (+0%)

USD 1.89B
SLIM 0.00 % 0.50 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 52.71% 94% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 52.71% 94% A 95% A
Trailing 12 Months  
Capital Gain 39.08% 85% B 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.08% 85% B 86% B+
Trailing 5 Years  
Capital Gain 5.09% 82% B 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.09% 82% B 41% F
Average Annual (5 Year Horizon)  
Capital Gain -0.90% 50% F 40% F
Dividend Return -0.90% 50% F 36% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 59.60% 53% F 31% F
Risk Adjusted Return -1.51% 50% F 37% F
Market Capitalization 0.62B 96% N/A 86% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 37.22 5% 4%
Price / Cash Flow Ratio 998.00 2% 0%
Price/Free Cash Flow Ratio -34.37 96% 96%
Management Effectiveness  
Return on Equity -75.27% 45% 25%
Return on Invested Capital -23.63% 49% 31%
Return on Assets -6.54% 71% 39%
Debt to Equity Ratio 711.10% 7% 3%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.